Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE 102)
NCT Number:
NCT05111626
Phase:
I
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Esophagus, Stomach
Study Objectives:
This is a double-blind, randomized, placebo-controlled multicenter Phase 1b/3 study to
evaluate the safety, tolerability, efficacy and pharmacokinetics (PK) of bemarituzumab +
mFOLFOX6 + nivolumab versus placebo + mFOLFOX6+ nivolumab in subjects with
advanced gastric or gastroesophageal junction adenocarcinoma that express FGFR2b
and who have not received prior treatment for unresectable or metastatic disease.
Study Documents
(MUSC NetID required for document access)